Patents by Inventor Kohji Hanasaki

Kohji Hanasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NPY Y5 antagonist
    Patent number: 8115027
    Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound or the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: February 14, 2012
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yasuyuki Kawanishi, Hideyuki Takenaka, Kohji Hanasaki, Tetsuo Okada
  • Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
    Patent number: 8088924
    Abstract: It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(?O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: January 3, 2012
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yukio Tada, Yasuyoshi Iso, Kohji Hanasaki
  • NPY Y5 ANTAGONIST
    Publication number: 20110039802
    Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylone, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof
    Type: Application
    Filed: July 2, 2010
    Publication date: February 17, 2011
    Inventors: Yasuyuki KAWANISHI, Hideyuki TAKENAKA, Kohji HANASAKI, Tetsuo OKADA
  • NPY Y5 ANTAGONIST
    Publication number: 20100292500
    Abstract: The present invention provides a pharmaceutical composition for use as art NPY Y5 receptor antagonist comprising a compound or the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: July 2, 2010
    Publication date: November 18, 2010
    Inventors: Yasuyuki KAWANISHI, Hideyuki TAKENAKA, Kohji HANASAKI, Tetsuo OKADA
  • NPY Y5 antagonist
    Patent number: 7781461
    Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: August 24, 2010
    Inventors: Yasuyuki Kawanishi, Hideyuki Takenaka, Kohji Hanasaki, Tetsuo Okada
  • Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter
    Publication number: 20100081686
    Abstract: It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(?O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.
    Type: Application
    Filed: September 2, 2009
    Publication date: April 1, 2010
    Inventors: Yukio TADA, Yasuyoshi ISO, Kohji HANASAKI
  • Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
    Patent number: 7652141
    Abstract: It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(?O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: January 26, 2010
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yukio Tada, Yasuyoshi Iso, Kohji Hanasaki
  • Compounds exhibiting type X sPLA2 inhibiting effect
    Publication number: 20090286796
    Abstract: A compound represented by the general formula: wherein R20 is —CH2COOH and the like; R21 is —COCONH2 and the like; R22 is C4-C6 alkyl; and the like; R23 is —CH2—R18 wherein R18 is aryl and the like; R24 is hydrogen or C1-C6 alkyl and the like; an optical active compound, a prodrug thereof, or a pharmaceutically acceptable salt, or a solvate having type X sPLA2 inhibitory effect was found.
    Type: Application
    Filed: July 24, 2009
    Publication date: November 19, 2009
    Inventors: Tomoyuki Ogawa, Kaoru Seno, Kohji Hanasaki, Minoru Ikeda, Takashi Ono
  • Antipruritics
    Publication number: 20080312292
    Abstract: It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.
    Type: Application
    Filed: January 29, 2008
    Publication date: December 18, 2008
    Inventors: Kiyoshi Yasui, Yasuhide Morioka, Kohji Hanasaki
  • NPY Y5 antagonist
    Patent number: 7265130
    Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: September 4, 2007
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yasuyuki Kawanishi, Hideyuki Takenaka, Kohji Hanasaki, Tetsuo Okada
  • NPY Y5 antagonist
    Publication number: 20070015762
    Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof
    Type: Application
    Filed: September 14, 2006
    Publication date: January 18, 2007
    Inventors: Yasuyuki Kawanishi, Hideyuki Takenaka, Kohji Hanasaki, Tetsuo Okada
  • Compounds exhibiting type X sPLA2 inhibiting effect
    Publication number: 20060116379
    Abstract: A compound represented by the general formula: wherein R20 is —CH2COOH and the like; R21 is —COCONH2 and the like; R22 is C4-C6 alkyl; and the like; R23 is —CH2—R18 wherein R18 is aryl and the like; R24 is hydrogen or C1-C6 alkyl and the like; an optical active compound, a prodrug thereof, or a pharmaceutically acceptable salt, or a solvate having type X sPLA2 inhibitory effect was found.
    Type: Application
    Filed: November 16, 2005
    Publication date: June 1, 2006
    Inventors: Tomoyuki Ogawa, Kaoru Seno, Kohji Hanasaki, Minoru Ikeda, Takashi Ono
  • Compounds exhibiting X-type sPLAinhibiting effect
    Patent number: 7026318
    Abstract: A compound represented by the general formula: wherein R20 is —CH2COOH and the like; R21 is —COCONH2 and the like; R22 is C4–C6 alkyl; and the like; R23 is —CH2—R18 wherein R18 is aryl and the like; R24 is hydrogen or C1–C6 alkyl and the like; an optical active compound, a prodrug thereof, or a pharmaceutically acceptable salt, or a solvate having type X sPLA2 inhibitory effect was found.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: April 11, 2006
    Assignee: Shionogi & Co., Ltd.
    Inventors: Tomoyuki Ogawa, Kaoru Seno, Kohji Hanasaki, Minoru Ikeda, Takashi Ono
  • Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
    Publication number: 20060052411
    Abstract: It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(?O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.
    Type: Application
    Filed: June 29, 2005
    Publication date: March 9, 2006
    Inventors: Yukio Tada, Yasuyoshi Iso, Kohji Hanasaki
  • Pyridone derivatives having affinity for cannabinoid 2-type receptor
    Patent number: 6977266
    Abstract: It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): ? wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(?O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.
    Type: Grant
    Filed: December 26, 2001
    Date of Patent: December 20, 2005
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yukio Tada, Yasuyoshi Iso, Kohji Hanasaki
  • Remedies for cirrhosis
    Patent number: 6967200
    Abstract: It is provided that type-X sPLA2 inhibitors are useful in preventing or treating hepatocirrhosis.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: November 22, 2005
    Assignee: Shionogi & Co., Ltd.
    Inventors: Kohji Hanasaki, Minoru Ikeda, Takashi Ono
  • Human secretory type phospholipase A2
    Patent number: 6967095
    Abstract: This invention relates to a gene encoding human secretory type phospholipase A2 (PLA2). According to the invention, an expression vector having this gene, and a transformant having the expression vector are obtainable. The PLA2 protein can be produced by the culture of the transformant.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: November 22, 2005
    Assignee: Shionogi & Co., Ltd.
    Inventors: Jun Ishizaki, Noriko Suzuki, Kohji Hanasaki
  • Antipruritics
    Publication number: 20050101590
    Abstract: It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.
    Type: Application
    Filed: February 18, 2003
    Publication date: May 12, 2005
    Inventors: Kiyoshi Yasui, Yasuhide Morioka, Kohji Hanasaki
  • Human secretory type phospholipase A2
    Publication number: 20050074861
    Abstract: This invention relates to a gene encoding human secretory type phospholipase A2 (PLA2). According to the invention, an expression vector having this gene, and a transformant having the expression vector are obtainable. The PLA2 protein can be produced by the culture of the transformant.
    Type: Application
    Filed: August 25, 2003
    Publication date: April 7, 2005
    Applicant: Shionogi & Co., Ltd.
    Inventors: Jun Ishizaki, Noriko Suzuki, Kohji Hanasaki
  • Gene encoding novel human secretory phospholipase A2
    Patent number: 6872557
    Abstract: This invention relates to a gene encoding human secretory type phospholipase A2 (PLA2). According to the invention, an expression vector having this gene, and a transformant having the expression vector are obtainable. The PLA2 protein can be produced by the culture of the transformant.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: March 29, 2005
    Assignee: Shionogi & Co., Ltd.
    Inventors: Jun Ishizaki, Noriko Suzuki, Kohji Hanasaki